A Retrospective Study to Characterize Participants With Propionic Acidemia
← catalyst calendarNCT05769621 · readout in 42 d
Sponsored by ModernaTX, Inc. (industry) · MRNA — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
60estimated
Sites
29
Countries
Australia, Canada, France +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-06-16 | actual | When the study began enrolling |
| Primary completion | 2026-09-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-09-30 | estimated | The whole study's end, after follow-up |
| First posted | 2023-03-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Propionic Acidemia
Primary outcome
what the primary-completion date above is the date OFNumber of Annualized Clinical Event Committee (CEC)-adjudicated Metabolic Decompensation Events (MDEs)
measured Up to 10 years
Permalink · MRNA's whole pipeline · Catalyst calendar · Every registered study · What changed